Market Exclusive

Analyst Downgrades – ABIOMED (NASDAQ:ABMD) Stock Gets Downgraded By BTIG Research from Buy to Neutral

Analyst Ratings For ABIOMED (NASDAQ:ABMD)

Today, ABIOMED (NASDAQ:ABMD) stock was downgraded by BTIG Research from Buy to Neutral.

There are 2 hold ratings, 6 buy ratings on the stock.

The current consensus rating on ABIOMED (NASDAQ:ABMD) is Buy (Score: 2.75) with a consensus target price of $174.71 per share, a potential 2.48% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For ABIOMED (NASDAQ:ABMD)
ABIOMED (NASDAQ:ABMD) has insider ownership of 7.00% and institutional ownership of 89.37%.

Recent Trading Activity for ABIOMED (NASDAQ:ABMD)
Shares of ABIOMED closed the previous trading session at with shares trading hands.

Exit mobile version